Precede

Boston, United States Founded: 2021 • Age: 5 yrs
Circulating chromatin is profiled via liquid-biopsy platform for cancer diagnosis.

About Precede

Precede is a company based in Boston (United States) founded in 2021 by Rehan Verjee.. Precede has raised $57 million across 1 funding round from investors including Stealth. Precede offers products and services including Liquid Biopsy Platform. Precede operates in a competitive market with competitors including Guardant Health, GRAIL, Personalis, Thrive Earlier Detection and Delfi Diagnostics, among others.

  • Headquarter Boston, United States
  • Founders Rehan Verjee
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $57 M (USD)

    in 1 rounds

  • Latest Funding Round
    $57 M (USD), Series C

    Oct 10, 2023

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Precede

Precede offers a comprehensive portfolio of products and services, including Liquid Biopsy Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Profiles circulating chromatin from blood for gene activation analysis.

People of Precede
Headcount 10-50
Employee Profiles 29
Employee Profiles
People
Anatoly Myaskovsky
Senior Automation Engineer, Product Development
People
Humphrey Gardner
Consulting CMO
People
Anthony D'Ippolito
Principal Scientist
People
Mary McGillicuddy
Senior Clinical Project Manager

Unlock access to complete

Funding Insights of Precede

Precede has successfully raised a total of $57M through 1 strategic funding round. The most recent funding activity was a Series C round of $57 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 1
  • Last Round Series C — $57.0M
  • First Round

    (10 Oct 2023)

  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Oct, 2023 Amount Series C - Precede Valuation Stealth
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Precede

Precede has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Stealth. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Ruggedized industrial computers and peripherals are supplied for various sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Precede

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Precede

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Precede Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Precede

Precede operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Personalis, Thrive Earlier Detection and Delfi Diagnostics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Digital sequencing technology for cancer detection is developed.
domain founded_year HQ Location
Circulating tumor DNA is screened for early cancer detection.
domain founded_year HQ Location
Genomic sequencing and diagnosis software is provided for healthcare.
domain founded_year HQ Location
Blood-based liquid biopsy tests for multiple cancer detection are provided.
domain founded_year HQ Location
Provider of DNA sequencing for cancer detection
domain founded_year HQ Location
Provider of cell-free cancer liquid biopsy test
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Precede

When was Precede founded?

Precede was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Precede located?

Precede is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Who is the current CEO of Precede?

Rehan Verjee is the current CEO of Precede. They have also founded this company.

Is Precede a funded company?

Precede is a funded company, having raised a total of $57M across 1 funding round to date. The company's 1st funding round was a Series C of $57M, raised on Oct 10, 2023.

What does Precede do?

Precede was established in 2021 in Boston, United States, within the biotechnology sector focused on oncology. A genome-wide liquid-biopsy platform is utilized to analyze circulating chromatin and the DNA methylome. This approach supports cancer diagnosis and aids in the creation of precision medicines. Operations emphasize diagnostic services for early detection and therapeutic development in the healthcare field.

Who are the top competitors of Precede?

Precede's top competitors include Guardant Health, GRAIL and Personalis.

What products or services does Precede offer?

Precede offers Liquid Biopsy Platform.

Who are Precede's investors?

Precede has 1 investor. Key investors include Stealth.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available